Investing News NetworkJune 13, 2024Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyCardiol Therapeutics Inc.

投资新闻网2024年6月13日CardiolRx™的给药导致心包炎painCardiolRx™的主要疗效终点显着降低，也显示可减轻CRP89升高患者的炎症。89%的患者继续进入研究Cardiol Therapeutics Inc.的延长期。

(NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis.

（纳斯达克：CRDL）（TSX:CRDL）（“Cardiol”或“公司”）是一家临床阶段生命科学公司，专注于用于治疗心脏病的抗炎和抗纤维化疗法的研究和临床开发，今天报道了其II期开放标签MAvERIC试点研究的8周临床数据，该研究调查了CardiolRx™对症状性复发性心包炎患者的影响。

The data showed a substantial reduction in the primary efficacy endpoint of patient-reported pericarditis pain at the end of the 8-week treatment period ('TP'), as well as normalization of inflammation - as measured by C-reactive protein ('CRP' in 80% of patients with elevated CRP at baseline.'We are delighted to share the primary endpoint data from the MAvERIC-Pilot study, demonstrating that oral administration of our small molecule CardiolRx™ led to marked reductions in pericarditis pain and inflammation, which were remarkably comparable in magnitude to the changes reported following immunosuppressive biologic therapy commonly used in third-line treatment of recurrent pericarditis,' said David Elsley, Cardiol Therapeutics' President and Chief Executive Officer.

数据显示，在8周治疗期（“TP”）结束时，患者报告的心包炎疼痛的主要疗效终点显着降低，并且通过C反应蛋白（“CRP”）在80%的基线CRP升高的患者中测量炎症正常化。Cardiol Therapeutics总裁兼首席执行官David Elsley说：“我们很高兴分享MAvERIC试点研究的主要终点数据，证明口服我们的小分子CardiolRx™可显着降低心包炎疼痛和炎症，其程度与常用于复发性心包炎三线治疗的免疫抑制生物治疗后报告的变化相当。”。

'Based on the clinically meaningful impact of CardiolRx™ on the key symptom of this debilitating disease, we now anticipate that the totality of the MAvERIC-Pilot data will support advancing to a Phase III trial of CardiolRx™ designed to meet our objective of providing a more accessible and non.

“基于CardiolRx™对这种衰弱性疾病的关键症状的临床意义影响，我们现在预计，MAvERIC试点数据的总体将支持推进CardiolRx™的III期试验，以满足我们提供更易获得和不易获得的目标。